Search results
Articles 1–20. Professor of Pediatrics, Dana-Farber Cancer Institute and Harvard Medical School - Cited by 19,508 - Chemical Biology - Pediatrics - Pediatric Oncology - Cancer -...
Aug 23, 2012 · Abstract. Loren D Walensky is an Associate Professor of Pediatrics at Harvard Medical School, faculty member in the Department of Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Children’s Hospital Boston, and Medical Director of Dana-Farber’s Program in Cancer Chemical Biology.
People also ask
Who is Loren Walensky?
What does the Walensky laboratory do?
Where did Dr Walensky go to medical school?
Abstract. Loren D Walensky is an Associate Professor of Pediatrics at Harvard Medical School, faculty member in the Department of Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Children's Hospital Boston, and Medical Director of Dana-Farber's Program in Cancer Chemical Biology.
- Loren D Walensky
- 2012
Mar 26, 2024 · Pediatric oncologist Dr. Loren Walensky isn’t a Colby alum, but since 2005 he’s hosted students and young alumni in his award-winning Dana-Farber lab Dr. Loren Walensky works with Tommy DeAngelo ’22, a research technician at the Dana-Farber Cancer Institute in Boston.
Harvard Medical School. Loren David Walensky is an American physician-scientist and pediatric oncologist at the Dana–Farber Cancer Institute since 2003 and a professor of pediatrics at the Dana–Farber/Harvard Cancer Center. He researches peptides and oncogenic pathways. In 2013, Walensky became director of the joint MD/PhD program at ...
Professor of Pediatrics. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.
May 1, 2019 · Loren David Walensky, M.D., Ph.D. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Authors: Authors: Mourtada R, Herce HD, Yin DJ, Moroco JA, Wales TE, Engen JR, Walensky LD. Targeting BAX to drug death directly.
